10-K: Alphatec Holdings Reports 37% Revenue Increase in 2023 Annual Filing

Sentiment:

Annual Results 27 February 2024 4:52 PM

Alphatec Holdings, a medical technology company focused on spine disorders, announced a 37% increase in revenue for the year ended December 31, 2023, reaching $482.3 million.

Capital raiseThe company completed a public offering in October 2023, raising approximately $145.8 million in net proceeds.The company completed a registered securities offering in April 2023, raising approximately $57.5 million in net proceeds.

Better than expectedThe company's revenue growth of 37% significantly exceeded expectations.The company's surgical volume increased by 31%, indicating strong market adoption.The company's average revenue per surgery expanded by 7%, demonstrating increased utilization of its products.

Summary

Alphatec Holdings, a medical technology company specializing in spine surgery solutions, reported a total revenue of $482.3 million for the year ended December 31, 2023.
This represents a significant increase of $131.4 million, or 37%, compared to the $350.9 million reported in 2022.
The company attributes this growth to increased adoption of its integrated technologies and approach-specific procedures.
Since 2018, Alphatec has experienced a compound annual growth rate of approximately 40% in revenue.
The company completed a public offering in October 2023, raising approximately $145.8 million in net proceeds.
Alphatec also acquired a navigation-enabled robotics platform called 'Valence' for $55.0 million in April 2023.
The company's strategic initiatives include creating clinical distinction, compelling surgeon adoption, and elevating distribution.
Surgical volume grew by 31% and average revenue per surgery expanded by 7% in 2023 compared to 2022.
The company is focused on developing its Alpha InformatiX platform, which includes the EOS imaging system and SafeOp Neural InformatiX System.
Alphatec is expanding its international footprint, beginning with partnerships in Australia and New Zealand.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth, strategic acquisitions, and a focus on innovation. However, the company's history of net losses and reliance on external funding temper the overall sentiment slightly.

Positives

The company has demonstrated strong revenue growth, indicating increasing market acceptance of its products.
The acquisition of Valence and the development of Alpha InformatiX platform position the company for future innovation and growth.
The ATEC Experience program is successfully attracting and retaining surgeons, expanding the user base.
The company is expanding its international presence, opening new markets for its products.
The company has a comprehensive product portfolio designed to address various spine pathologies.
The company has a strong focus on research and development, with plans to launch 8-10 new products in 2024.

Negatives

The company has a history of net losses and expects to continue incurring net losses in the near future.
The company relies on third-party manufacturers and suppliers, which could lead to supply chain disruptions.
The company operates in a highly competitive market and faces competition from larger, well-established companies.
The company is subject to extensive government regulations, which could delay or prevent commercialization of new products.
The company's reliance on sales agents could affect its ability to market products efficiently and profitably.
The company's quarterly financial results could fluctuate significantly due to various factors.

Risks

The company's business plan relies on assumptions about the market for its products that may be incorrect.
The company faces intense competition from larger, well-capitalized medical device companies.
A significant percentage of the company's revenues are derived from sales of systems that include polyaxial pedicle screws.
The company relies on third-party licenses related to its polyaxial pedicle screw systems.
The company relies on a limited number of third parties to manufacture and supply its products.
The company depends on a single supplier for PEEK, a key raw material.
The company's sales depend on the ability of customers to obtain adequate third-party coverage and reimbursement.
The company's international operations are subject to various risks, including currency fluctuations and political instability.
The company may fail to realize the anticipated benefits of the Valence acquisition.
The company may be subject to federal and state healthcare laws, including fraud and abuse laws.
The company may fail to obtain governmental clearances or approvals for its future products.
The company may be unable to complete acquisitions or successfully integrate them.
The company is dependent on its senior management team and key surgeon advisors.
The company's business is dependent upon the effective operation of its information systems.
The company's operations are subject to risks from natural disasters and public health crises.
The company may need to raise additional funds in the future, which may not be available on acceptable terms.
Covenants in the company's loan documents may restrict its business and operations.
The company's stock price may fluctuate significantly.
The company may become involved in securities class action litigation.
The company's ability to use its net operating loss carryforwards may be limited.
The company could be subject to changes in tax rates, new tax legislation, or additional tax liabilities.
The company may be subject to product liability claims that exceed its insurance coverage.
The company may be subject to intellectual property litigation that could be costly and prevent it from marketing its products.

Future Outlook

The company expects continued growth in the number of products sold per surgery, surgical volume, and revenue per surgery. They also intend to continue to pioneer spine innovation that improves surgical outcomes and focus international investments in economically attractive markets with strong surgeon influence.

Management Comments

The company believes its future success will be fueled by increasing adoption of new and existing integrated technologies.
The company feels that ATEC is well-positioned to continue to capitalize on spine market dynamics.
The application of the team's deep spine know-how, coupled with a willingness to invest holistically in each of the technologies integrated into all of ATEC's procedural approaches continues to increasingly compel surgeons and sales talent to partner with us.

Industry Context

The announcement reflects a trend of increasing innovation and competition in the spinal implant industry. The company's focus on integrated technologies and approach-specific procedures aligns with the industry's move towards more comprehensive and outcome-driven solutions. The acquisition of Valence and the development of the Alpha InformatiX platform are examples of the company's efforts to differentiate itself in a competitive market.

Comparison to Industry Standards

The 37% revenue growth reported by Alphatec significantly exceeds the average growth rate for the medical device industry, which typically ranges from 5% to 10%.
Competitors like Medtronic, Johnson & Johnson, and Stryker, while having larger market shares, often experience slower growth rates due to their size and diversification.
Alphatec's focus on spine-specific solutions and its integrated technology approach is a differentiator compared to competitors with broader product portfolios.
The company's 40% compound annual growth rate since 2018 indicates a strong market share expansion, which is notable compared to the more established players in the industry.
The company's investment in surgeon training programs, such as the ATEC Experience, is a strategy that aligns with industry best practices for driving adoption of new technologies.
The acquisition of Valence is a strategic move to integrate robotics and navigation into spine procedures, which is a growing trend in the industry.
The company's focus on data-driven solutions through the Alpha InformatiX platform is also in line with the industry's increasing emphasis on evidence-based medicine.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Amendment to 2016 Employment Inducement Award Plan	Increased the shares of common stock available for issuance under the Inducement Plan by 600,000 shares, resulting in total common stock available for issuance under the plan of 4,150,000 shares.	October 25, 2023	Increases the company's ability to attract and retain talent through equity-based compensation.
Amendment to 2016 Equity Incentive Plan	Increased the shares of common stock available for issuance under the 2016 Plan by 9,300,000 shares, resulting in total common stock reserved for issuance under the 2016 Plan of 26,383,333 shares.	June 14, 2023	Increases the company's ability to attract and retain talent through equity-based compensation.
Amendment to 2017 Distributor Inducement Plan	Increased the shares of common stock available for issuance under the Distributor Inducement Plan by 500,000 shares, resulting in total common stock available for issuance under the plan of 1,500,000 shares.	October 26, 2023	Increases the company's ability to incentivize sales agents through equity-based compensation.
Amendment to 2017 Development Services Plan	Increased the shares of common stock available for issuance under the Development Services Plan by 2,000,000 shares, resulting in total common stock available for issuance under the plan of 10,000,000 shares.	October 26, 2023	Increases the company's ability to incentivize third-party developers through equity-based compensation.
Amendment to 2007 Employee Stock Purchase Plan	Increased the number of shares of common stock available for purchase under the ESPP by 1,500,000 shares, resulting in total common stock reserved for issuance under the ESPP of 3,637,449 shares.	June 14, 2023	Increases the company's ability to incentivize employees through equity-based compensation.

Legal Proceedings

The company was involved in a patent infringement lawsuit with NuVasive, Inc., which was settled in June 2022.
The company is and may become involved in various legal proceedings arising from its business activities.

Related Party Transactions

The company purchases inventory from an affiliate of Squadron Capital, LLC, whose President and Director, David Pelizzon, serves on the company's Board of Directors.

Stakeholder Impact

Shareholders may benefit from the company's strong revenue growth and strategic initiatives.
Employees may benefit from the company's growth and expansion, as well as equity-based compensation plans.
Customers (surgeons and hospitals) may benefit from the company's innovative products and training programs.
Suppliers may benefit from the company's increasing demand for its products.
Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

The company intends to continue to pioneer spine innovation that improves surgical outcomes.
The company expects continued growth in the number of products sold into each surgery, surgical volume and revenue per surgery.
The company intends to continue to add clinically astute and exclusive independent sales agents and direct sales representatives.
The company intends to focus its international investments in economically attractive markets with strong surgeon influence and reasonable regulatory pathways.
The company expects to launch 8-10 new products during 2024.
The company is seeking to further develop and commercialize its vision for Valence.

Key Dates

Date	Description
October 18, 2004	Supply Agreement between Alphatec Spine, Inc. and Invibio, Inc.
March 2005	Alphatec Holdings, Inc. incorporated in Delaware.
December 13, 2004	Letter of Amendment in respect of the Supply Agreement between Alphatec Spine, Inc. and Invibio, Inc.
May 28, 1976	Date before which a medical device was legally marketed and for which a PMA is not required.
July 1991	Department of Health and Human Services Office of Inspector General (OIG) issued a series of regulations, known as the safe harbors.
March 26, 2013	OIG issued a Special Fraud Alert entitled Physician-Owned Entities.
April 1, 2013	Reductions to Medicare payments to providers of 2% per fiscal year went into effect.
September 26, 2014	The Company entered into a Settlement and Release Agreement with Orthotec, LLC.
September 14, 2016	Employment Agreement with Craig E. Hunsaker.
October 4, 2016	The Companys Board of Directors adopted the 2016 Employment Inducement Award Plan.
October 2, 2017	Employment Agreement by and among Patrick S. Miles, Alphatec Spine, Inc., and Alphatec Holdings, Inc.
March 8, 2018	Securities Purchase Agreement between Alphatec Holdings, Inc. and each purchaser named in the signature pages thereto.
April 16, 2018	Amended and Restated Registration Rights Agreement.
May 31, 2018	EOS issued 4,344,651 OCEANEs denominated in Euros, due May 2023.
November 6, 2018	Registration Rights Agreement between Alphatec Holdings, Inc., and Squadron Medical Finance Solutions LLC and Tawani Holdings LLC.
February 12, 2019	Insider Trading Policy updated and effective.
August 2, 2019	Employment Agreement by and among Eric Dasso, Alphatec Spine, Inc., and Alphatec Holdings, Inc.
June 21, 2019	Registration Rights Agreement between Alphatec Holdings, Inc., and Squadron Medical Finance Solutions LLC and Tawani Holdings LLC.
December 4, 2019	Lease Agreement by and between Alphatec Spine, Inc. and RAF Pacifica Group Real Estate Fund IV, LLC; ARKA Monterey Park, LLC, and 170 Arrowhead Partners, LLC.
May 29, 2020	Registration Rights Agreement between Alphatec Holdings, Inc., and Squadron Medical Finance Solutions LLC and Tawani Holdings LLC.
June 21, 2021	Second Amended and Restated 2007 Employee Stock Purchase Plan.
December 16, 2020	Registration Rights Agreement.
February 18, 2021	Severance Agreement between Patrick S. Miles and Alphatec Spine, Inc and Severance Agreement between Craig E. Hunsaker and Alphatec Spine, Inc.
February 1, 2021	Commencement date of the 10-year operating lease for the headquarters in Carlsbad, California.
April 6, 2021	Employment Agreement with J. Todd Koning.
August 10, 2021	Indenture between Alphatec Holdings, Inc. and U.S. Bank National Association, as trustee.
September 29, 2022	Credit Agreement between Alphatec Holdings, Inc., Alphatec Spine, Inc. and the other borrowers from time to time party thereto, the guarantors from time to time party thereto, MidCap Financial Trust and the other lenders from time to time party thereto, and MidCap Funding IV Trust, as administrative agent.
January 6, 2023	Credit, Security and Guaranty Agreement between Alphatec Holdings, Inc., as borrower, the guarantors from time to time party thereto, the lenders from time to time party thereto, and Wilmington Trust, National Association, as agent.
April 19, 2023	Asset Purchase Agreement with Integrity Implants Inc. and Fusion Robotics, LLC and completion of a registered securities offering.
June 15, 2023	Fifth Amendment to the Alphatec Holdings, Inc. 2016 Equity Incentive Plan and Third Amendment to the Alphatec Holdings, Inc. 2007 Employee Stock Purchase Plan.
July 19, 2023	Form of Severance Agreement between J. Todd Koning, Dave Sponsel and Eric Dasso and Alphatec Spine, Inc.
September 28, 2023	The Company drew the additional $50.0 million (the delayed draw term loan(s) or the DDTL) under the Braidwell Term Loan.
October 25, 2023	Sixth Amendment to the Alphatec Holdings, Inc. 2016 Employment Inducement Award Plan.
October 26, 2023	The Companys Board of Directors approved an amendment to the Companys Distributor Inducement Plan and Development Services Plan.
October 27, 2023	Completion of an underwritten public offering.
November 17, 2023	The underwriters exercised their option to purchase 470,769 additional shares.
December 31, 2023	End of fiscal year.

Keywords

spine surgery, medical technology, spinal implants, robotics, navigation, EOS imaging, surgical procedures, orthopedics, healthcare, medical devices

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.